Reactive Oxygen Species Regulation of Chemoresistance and Metastatic Capacity of Melanoma: Role of the Cancer Stem Cell Marker CD271

BRAF mutations are present in 30–50% of cases of cutaneous melanoma, and treatment with selective BRAF and MEK inhibitors has been introduced. However, the development of resistance to these drugs often occurs. Chemo-resistant melanoma cells show increased expression of CD271, a stem cell marker that features increased migration. Concordantly, resistance to the selective inhibitor of oncogenic BRAFV600E/K, vemurafenib, is mediated by the increased expression of CD271. It has recently been shown that the BRAF pathway leads to an overexpression of the NADPH oxidase Nox4, which produces reactive oxygen species (ROS). Here, we examined in vitro how Nox-derived ROS in BRAF-mutated melanoma cells regulates their drug sensitivity and metastatic potential. We demonstrated that DPI, a Nox inhibitor, reduced the resistance of a melanoma cell line (SK-MEL-28) and a primary culture derived from a BRAFV600E-mutated biopsy to vemurafenib. DPI treatment affected the expression of CD271 and the ERK and Akt signaling pathways, leading to a drop in epithelial–mesenchymal transition (EMT), which undoubtedly promotes an invasive phenotype in melanoma. More importantly, the scratch test demonstrated the efficacy of the Nox inhibitor (DPI) in blocking migration, supporting its use to counteract drug resistance and thus cell invasion and metastasis in BRAF-mutated melanoma.

[1]  P. Millner,et al.  Hyaluronic-Acid-Tagged Cubosomes Deliver Cytotoxics Specifically to CD44-Positive Cancer Cells , 2022, Molecular pharmaceutics.

[2]  R. Dummer,et al.  Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression , 2021, Cancer Research.

[3]  T. Brabletz,et al.  Dynamic EMT: a multi‐tool for tumor progression , 2021, The EMBO journal.

[4]  L. Guillo,et al.  Expression of the cancer stem cell marker OCT4 is associated with worse prognosis and survival in cutaneous melanoma , 2021, Melanoma research.

[5]  G. Pellacani,et al.  The Interplay between HGF/c-met Axis and Nox4 in BRAF Mutated Melanoma , 2021, International journal of molecular sciences.

[6]  E. Sikora,et al.  Inhibition of NADPH Oxidases Activity by Diphenyleneiodonium Chloride as a Mechanism of Senescence Induction in Human Cancer Cells , 2020, Antioxidants.

[7]  T. Yau,et al.  Akt3 induces oxidative stress and DNA damage by activating the NADPH oxidase via phosphorylation of p47phox , 2020, Proceedings of the National Academy of Sciences.

[8]  T. Redmer,et al.  Decoding the Role of CD271 in Melanoma , 2020, Cancers.

[9]  S. Dalle,et al.  EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment , 2020, Cancers.

[10]  Yuqing Xiong,et al.  Inactivating p53 is essential for nerve growth factor receptor to promote melanoma-initiating cell-stemmed tumorigenesis , 2020, Cell Death & Disease.

[11]  Rosalin Mishra,et al.  BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels , 2020, Cancers.

[12]  Weinan Guo,et al.  A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[13]  R. Jensen,et al.  PAC1 regulates receptor tyrosine kinase transactivation in a reactive oxygen species-dependent manner , 2019, Peptides.

[14]  Chen Li,et al.  CD271 is a molecular switch with divergent roles in melanoma and melanocyte development , 2019, Scientific Reports.

[15]  C. Longo,et al.  Melanoma types by in vivo reflectance confocal microscopy correlated with protein and molecular genetic alterations: A pilot study , 2019, Experimental dermatology.

[16]  R. Plummer,et al.  Harnessing autophagy to overcome mitogen‐activated protein kinase kinase inhibitor‐induced resistance in metastatic melanoma , 2018, The British journal of dermatology.

[17]  Edward J Merino,et al.  Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma , 2018, Journal of Cancer.

[18]  J. McCubrey,et al.  Nuclear Nox4 interaction with prelamin A is associated with nuclear redox control of stem cell aging , 2018, Aging.

[19]  R. Kefford,et al.  Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma , 2018, Oncogenesis.

[20]  D. Hill,et al.  How breakthroughs in translational research have impacted treatment strategies for melanoma , 2018, The British journal of dermatology.

[21]  R. Dummer,et al.  The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma , 2017, Nature Communications.

[22]  P. Ascierto,et al.  Phenotype characterization of human melanoma cells resistant to dabrafenib , 2017, Oncology reports.

[23]  M. Polak,et al.  NADPH Oxidase NOX4 Is a Critical Mediator of BRAFV600E-Induced Downregulation of the Sodium/Iodide Symporter in Papillary Thyroid Carcinomas. , 2017, Antioxidants & redox signaling.

[24]  F. Afaq,et al.  Potential therapeutic targets of epithelial-mesenchymal transition in melanoma. , 2017, Cancer letters.

[25]  T. Redmer,et al.  The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells , 2017, Oncogenesis.

[26]  Marie Perier-Muzet,et al.  ZEB1‐mediated melanoma cell plasticity enhances resistance to MAPK inhibitors , 2016, EMBO molecular medicine.

[27]  R. Scolyer,et al.  Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? , 2016, European journal of cancer.

[28]  Samantha E. Boyle,et al.  CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity. , 2016, Cancer research.

[29]  M. Herlyn,et al.  Oncogenic BRAF-Mediated Melanoma Cell Invasion. , 2016, Cell reports.

[30]  P. Abbe,et al.  Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib , 2015, Cell Discovery.

[31]  H. Konishi,et al.  Inhibition of NADPH oxidase 4 induces apoptosis in malignant mesothelioma: Role of reactive oxygen species. , 2015, Oncology reports.

[32]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[33]  G. Argenziano,et al.  CD271 is expressed in melanomas with more aggressive behaviour, with correlation of characteristic morphology by in vivo reflectance confocal microscopy , 2015, The British journal of dermatology.

[34]  R. Dellinger,et al.  Updates of reactive oxygen species in melanoma etiology and progression. , 2014, Archives of biochemistry and biophysics.

[35]  G. Murphy,et al.  Stem cells and targeted approaches to melanoma cure. , 2014, Molecular aspects of medicine.

[36]  G. Long,et al.  Systemic treatment for BRAF-mutant melanoma: where do we go next? , 2014, The Lancet. Oncology.

[37]  P. Bahadoran,et al.  CD271 is an imperfect marker for melanoma initiating cells , 2014, Oncotarget.

[38]  Yun-Ju Chen,et al.  Cyclooxygenase-2 expression is up-regulated by 2-aminobiphenyl in a ROS and MAPK-dependent signaling pathway in a bladder cancer cell line. , 2012, Chemical research in toxicology.

[39]  H. Moch,et al.  Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. , 2011, Cancer research.

[40]  E. Gazzano,et al.  Classical inhibitors of NOX NAD(P)H oxidases are not specific. , 2008, Current drug metabolism.

[41]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.